Tai-Chung Tseng, PhD

Biography

Dr. Tai-Chung Tseng is an Associate Professor and an attending physician at National Taiwan University Hospital in Taipei, Taiwan. He completed his doctoral research under the mentorship of Prof. Jia-Horng Kao and received his Ph.D. degree in 2013. Dr. Tseng's research primarily focuses on the long-term prognosis of chronic hepatitis B (CHB) carriers, particularly investigating how viral and host factors influence disease outcomes.
One of Dr. Tseng's most significant contributions to the field is his work on quantifying hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) levels. He identified that HBsAg levels below 1000 IU/mL are indicative of inactive CHB, thereby helping to identify patients at minimal risk of developing hepatocellular carcinoma (HCC). Moreover, he demonstrated that an HBcrAg level below 10 KU/mL is a key marker for identifying HBeAg-negative patients who are at a higher risk for HCC, particularly those in the "gray zone" for antiviral treatment.
Dr. Tseng's findings have been published as the first author in leading gastrointestinal journals, including Gastroenterology, Gut, Journal of Hepatology, and Hepatology, and have been validated by independent research groups. His work has made a significant impact on the understanding and management of HBV, especially in predicting outcomes like HBsAg clearance and the development of HCC in a large cohort of HBV carriers.
Recently, Dr. Tseng has shifted his research focus towards HBV immunology, with the ultimate goal of achieving a functional cure for HBV through safe and effective immunotherapy. His continued efforts in this field hold great promise for the future of HBV treatment and patient care.